Steven B. Ketchum Sells 879,241 Shares of Amarin Co. plc (AMRN) Stock

Amarin Co. plc (NASDAQ:AMRN) insider Steven B. Ketchum sold 879,241 shares of the business’s stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $11.10, for a total value of $9,759,575.10. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Shares of NASDAQ:AMRN opened at $13.83 on Friday. The company has a market cap of $3.80 billion, a P/E ratio of -56.64 and a beta of 0.95. The company has a quick ratio of 1.13, a current ratio of 1.43 and a debt-to-equity ratio of -1.25. Amarin Co. plc has a 12-month low of $2.35 and a 12-month high of $14.70.

Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.03). The company had revenue of $52.64 million during the quarter, compared to the consensus estimate of $54.88 million. The company’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.04) EPS. sell-side analysts expect that Amarin Co. plc will post -0.38 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of AMRN. Private Advisor Group LLC boosted its stake in Amarin by 81.8% in the 1st quarter. Private Advisor Group LLC now owns 64,293 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 28,929 shares during the period. DRW Securities LLC boosted its stake in Amarin by 45.1% in the 1st quarter. DRW Securities LLC now owns 80,400 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 25,000 shares during the period. Claraphi Advisory Network LLC boosted its stake in Amarin by 637.3% in the 1st quarter. Claraphi Advisory Network LLC now owns 85,309 shares of the biopharmaceutical company’s stock worth $257,000 after purchasing an additional 73,738 shares during the period. Northern Trust Corp boosted its stake in Amarin by 20.9% in the 2nd quarter. Northern Trust Corp now owns 113,327 shares of the biopharmaceutical company’s stock worth $350,000 after purchasing an additional 19,590 shares during the period. Finally, TD Asset Management Inc. boosted its stake in Amarin by 54.4% in the 2nd quarter. TD Asset Management Inc. now owns 134,207 shares of the biopharmaceutical company’s stock worth $415,000 after purchasing an additional 47,300 shares during the period. Institutional investors and hedge funds own 38.27% of the company’s stock.

AMRN has been the subject of a number of recent research reports. Zacks Investment Research downgraded Amarin from a “hold” rating to a “sell” rating in a research note on Tuesday, July 24th. ValuEngine downgraded Amarin from a “buy” rating to a “hold” rating in a research note on Saturday, July 28th. Citigroup boosted their price objective on Amarin from $5.00 to $17.00 and gave the company a “reduce” rating in a research note on Tuesday. Cantor Fitzgerald reiterated a “buy” rating and set a $10.00 price objective on shares of Amarin in a research note on Monday. Finally, Jefferies Financial Group boosted their price objective on Amarin from $7.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $13.20.

Amarin Company Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Recommended Story: Google Finance Portfolio

Insider Buying and Selling by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply